2024
Endpoints for clinical trials in type 1 diabetes drug development
Galderisi A, Marks B, DiMeglio L, de Beaufort C. Endpoints for clinical trials in type 1 diabetes drug development. The Lancet Diabetes & Endocrinology 2024, 12: 297-299. PMID: 38663944, PMCID: PMC11230104, DOI: 10.1016/s2213-8587(24)00097-4.Peer-Reviewed Original ResearchGlucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2024, 190: l7-l7. PMID: 38668689, DOI: 10.1093/ejendo/lvae042.Peer-Reviewed Original Research
2023
Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity
Galderisi A, Tricò D, Lat J, Samuels S, Weiss R, Van Name M, Pierpont B, Santoro N, Caprio S. Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity. JCI Insight 2023, 8: e165709. PMID: 37847560, PMCID: PMC10721315, DOI: 10.1172/jci.insight.165709.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell functionIncretin effectBeta-cell functionInsulin sensitivityInsulin secretionGlucose levelsCell functionIsoglycemic intravenous glucose infusionGreater insulin sensitivityIntravenous glucose infusionPubertal transitionGlucose tolerance testGLP-17Glucagon suppressionGlucose infusionObesityLongitudinal increaseBaselineOGTTEffect groupGreater increaseLongitudinal trajectoriesSecretionGroupGlucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2023, 189: k19-k24. PMID: 37952170, DOI: 10.1093/ejendo/lvad147.Peer-Reviewed Original ResearchConceptsClassical congenital adrenal hyperplasiaClassical CAHCongenital adrenal hyperplasiaContinuous glucose monitoringLower cortisol concentrationsGlucose patternsAdrenal hyperplasiaCortisol concentrationsGlucose monitoringFludrocortisone replacement therapySensor glucose valuesHydrocortisone doseAcute illnessAsymptomatic hypoglycemiaWhole cohortNighttime hypoglycemiaReplacement therapyPercentage of timeObservational studyGlucose profilesGlycemic patternsSerial measuresGlucose valuesDaily cortisolHypoglycemiaQuantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 2023, 66: 2189-2199. PMID: 37712956, PMCID: PMC10627950, DOI: 10.1007/s00125-023-06011-5.Peer-Reviewed Original ResearchConceptsType 1 diabetesBeta-cell functionInsulin secretionFunctional beta-cell massEarly pre-symptomatic stagesCell functionPre-symptomatic phaseBeta-cell massDisease-modifying interventionsPre-symptomatic stageContinuous glucose monitoringIslet autoimmunityInsulin sensitivityDisease progressionGlucose profilesInvasive measuresPreclinical stageMetabolic testsProgressive lossDiabetesMetabolic changesGlucose monitoringAvailable testsMeasurable changesOGTTSumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Golubic R, Ismail M, Josipovic M, Kennet J, Galderisi A, Evans M. Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes Obesity And Metabolism 2023, 25: 3059-3063. PMID: 37312648, DOI: 10.1111/dom.15176.Peer-Reviewed Original ResearchConceptsPlacebo-controlled cross-over trialIntravenous glucose tolerance testGlucose tolerance testCross-over trialGlucose effectivenessTolerance testInsulin sensitivityInsulin secretionHyperinsulinaemic euglycaemic clampControl blood glucoseGlucoregulatory roleOverweight adultsOverweight humansEuglycaemic clampInsulin levelsGlucose excursionsBlood glucoseReceptor agonistMouse modelGlucose homeostasisSumatriptanPlaceboSecretionTrialsHumansNeurosteroid pathway derangement in asphyctic infants treated with hypothermia: an untargeted metabolomic approach
Valerio E, Stocchero M, Pirillo P, D’Errico I, Bonadies L, Galderisi A, Giordano G, Baraldi E. Neurosteroid pathway derangement in asphyctic infants treated with hypothermia: an untargeted metabolomic approach. EBioMedicine 2023, 92: 104636. PMID: 37257315, PMCID: PMC10244906, DOI: 10.1016/j.ebiom.2023.104636.Peer-Reviewed Original ResearchConceptsAsphyctic infantsHypoxic-ischemic encephalopathyHealthy newbornsPerinatal asphyxiaMetabolic effectsSingle-center longitudinal studyDays of lifeTherapeutic hypothermiaUrinary metabolomePathobiological mechanismsSteroid levelsInfantsHypothermiaSteroidogenesis pathwayUntargeted metabolomics approachNewbornsSteroid contentTranslational researchLongitudinal studyPotential roleAsphyxiaEncephalopathyMetabolomics approachPathway analysisUntargeted metabolomicsBeta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi A. Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us. Pediatric Endocrinology Diabetes And Metabolism 2023, 29: 1-3. PMID: 37218722, PMCID: PMC10226454, DOI: 10.5114/pedm.2023.126360.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBeta-cell functionType 1 diabetesIslet autoimmunityCell functionFunctional beta-cell massDisease-modifier drugsUnderlying autoimmune processPre-symptomatic phaseBeta-cell massSymptomatic diabetesAutoimmune processClinical onsetSurrogate markerDiabetes progressionC-peptideInsulin secretionModifier drugsEarly changesDiabetesMetabolic changesDysglycaemiaAutoimmunityT1DOnsetModifier treatmentScreening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis
Weiss L, Reix P, Mosnier-Pudar H, Ronsin O, Beltrand J, Reynaud Q, Mely L, Burgel P, Stremler N, Rakotoarisoa L, Galderisi A, Perge K, Bendelac N, Abely M, Kessler L. Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis. Diabetes & Metabolism 2023, 49: 101444. PMID: 37030530, DOI: 10.1016/j.diabet.2023.101444.Peer-Reviewed Original ResearchConceptsGlucose tolerance abnormalitiesCystic fibrosis-related diabetesTolerance abnormalitiesCystic fibrosisAnnual oral glucose tolerance testOral glucose tolerance testGlucose tolerance testLong asymptomatic periodStage of diabetesNew comorbiditiesAsymptomatic periodClinical profileTolerance testNew diagnostic toolsPathophysiological knowledgeDiabetesNutritional outcomesPatientsFibrosisAbnormalitiesScreening strategyLife expectancyDiagnostic toolScreening methodComorbiditiesAnswering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries
Galderisi A, Sherr J. Answering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries. The Lancet Diabetes & Endocrinology 2023, 11: 300-301. PMID: 37004711, DOI: 10.1016/s2213-8587(23)00085-2.Commentaries, Editorials and LettersClinical features of neonatal COVID-19
Galderisi A, Lista G, Cavigioli F, Trevisanuto D. Clinical features of neonatal COVID-19. Seminars In Fetal And Neonatal Medicine 2023, 28: 101430. PMID: 37005209, PMCID: PMC10036147, DOI: 10.1016/j.siny.2023.101430.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSARS-CoV-2 infectionClinical featuresNeonatal COVID-19Infected mothersHealthy newbornsPsychological health problemsEfforts of cliniciansEpidemiological dataHealth problemsAge groupsInfectionFirst dayHealthcare systemCOVID-19COVID-19 pandemicNewbornsDifferential effectsEntire populationAdditional burdenComorbiditiesPandemicComplicationsNeonatesCliniciansMassive research effortA New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes
Schiavon M, Galderisi A, Basu A, Kudva Y, Cengiz E, Man C. A New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 25: 270-278. PMID: 36648253, PMCID: PMC10066780, DOI: 10.1089/dia.2022.0397.Peer-Reviewed Original ResearchObstructive sleep apnea (OSA) is associated with the impairment of beta-cell response to glucose in children and adolescents with obesity
Umano G, Galderisi A, Aiello F, Martino M, Camponesco O, Di Sessa A, Marzuillo P, Alfonso P, Miraglia del Giudice E. Obstructive sleep apnea (OSA) is associated with the impairment of beta-cell response to glucose in children and adolescents with obesity. International Journal Of Obesity 2023, 47: 257-262. PMID: 36670156, PMCID: PMC10113157, DOI: 10.1038/s41366-023-01257-w.Peer-Reviewed Original ResearchConceptsMild obstructive sleep apneaObstructive sleep apneaOral glucose tolerance testSevere obstructive sleep apneaInsulin secretionSleep apneaPlasma glucoseCardio-respiratory polygraphyTotal insulin secretionApnea-hypopnea indexOxygen desaturation indexBeta-cell responseGlucose tolerance testBeta-cell functionDynamic insulin secretionSpearman correlation testOral minimal modelOGTT studyReleasable insulinOSA severityDesaturation indexPediatric clinicTolerance testInsulin sensitivityLow prevalence
2022
β-Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a 2-Hour 7-Sample OGTT
Galderisi A, Evans-Molina C, Martino M, Caprio S, Cobelli C, Moran A. β-Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a 2-Hour 7-Sample OGTT. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 1376-1386. PMID: 36546354, PMCID: PMC10188312, DOI: 10.1210/clinem/dgac740.Peer-Reviewed Original ResearchGlucose-to-lactate ratio and neurodevelopment in infants with hypoxic-ischemic encephalopathy: an observational study
Galderisi A, Tordin M, Suppiej A, Cainelli E, Baraldi E, Trevisanuto D. Glucose-to-lactate ratio and neurodevelopment in infants with hypoxic-ischemic encephalopathy: an observational study. European Journal Of Pediatrics 2022, 182: 837-844. PMID: 36484862, PMCID: PMC9899169, DOI: 10.1007/s00431-022-04694-3.Peer-Reviewed Original ResearchConceptsHypoxic-ischemic encephalopathyTherapeutic hypothermiaNeurodevelopmental outcomesLactate ratioDay 1Severe hypoxic-ischemic encephalopathyNew risk markerSevere hypoNeonatal hypoglycemiaMetabolic outcomesRisk markersObservational studyMetabolic variablesDay 2InfantsLactate concentrationEncephalopathyLactate kineticsNeurodevelopmentMetabolic fuelsNeonatesStrongest predictorHypothermiaOutcomesGlucoseAdipose Tissue Insulin Resistance Is Not Associated With Changes in the Degree of Obesity in Children and Adolescents
Halloun R, Galderisi A, Caprio S, Weiss R. Adipose Tissue Insulin Resistance Is Not Associated With Changes in the Degree of Obesity in Children and Adolescents. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 1053-1060. PMID: 36469736, PMCID: PMC10306082, DOI: 10.1210/clinem/dgac700.Peer-Reviewed Original ResearchConceptsAdipose tissue insulin resistanceDegree of obesityTissue insulin resistanceWhole-body insulin sensitivityTissue insulin sensitivityInsulin resistanceInsulin sensitivityMultivariate analysisSecondary analysisBody mass index z-scorePediatric weight management clinicOral glucose tolerance testInsulin sensitivity/resistanceSkeletal muscle insulin resistanceFree fatty acid concentrationsWeight management clinicGlucose tolerance testMain outcome measuresDevelopment of obesityIndex z-scoreCarbohydrate-insulin modelMuscle insulin resistanceSensitivity/resistanceManagement clinicTolerance testISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr J, Schoelwer M, Dos Santos T, Reddy L, Biester T, Galderisi A, van Dyk J, Hilliard M, Berget C, DiMeglio L. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatric Diabetes 2022, 23: 1406-1431. PMID: 36468192, DOI: 10.1111/pedi.13421.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsGlucose variability increases during minimally invasive procedures in very preterm infants
Galderisi A, Res G, Guiducci S, Savio F, Brigadoi S, Forlani L, Mastrandrea B, Moschino L, Lolli E, Priante E, Trevisanuto D, Baraldi E. Glucose variability increases during minimally invasive procedures in very preterm infants. European Journal Of Pediatrics 2022, 182: 89-94. PMID: 36201017, PMCID: PMC9829573, DOI: 10.1007/s00431-022-04641-2.Peer-Reviewed Original ResearchConceptsVery preterm infantsContinuous glucose monitoringPreterm infantsGlucose variabilityNeonatal stressNappy changeInvasive proceduresMedian glucoseGlucose monitoringNon-invasive procedurePrimary outcomeAbsence of changesHeel prickMean glucoseNeonatal proceduresCare proceduresDay 2InfantsParental presenceGlucose variationCGM dataGlucoseSDNeonatesPrickMechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach
Tricò D, McCollum S, Samuels S, Santoro N, Galderisi A, Groop L, Caprio S, Shabanova V. Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach. Diabetes Care 2022, 45: 1841-1851. PMID: 35766976, PMCID: PMC9346992, DOI: 10.2337/dc22-0110.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell functionΒ-cell glucose sensitivityInsulin sensitivityGenetic risk profileMultiple oral glucose tolerance testsDifferent genetic risk profilesRisk profileMin oral glucose tolerance testLatent class trajectory analysisGlucose tolerance testImpaired insulin sensitivityPlasma glucose responseGlucose sensitivityClass 3Model-predicted probabilityClass 1Tolerance testProgressive impairmentMultiethnic cohortGlucose responseLongitudinal changesObesityTransient reductionInsulin kineticsSGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion